And if the system provides barriers, as Senator Sanders said, to drugs that could improve your care and your life and your health, then we haven't succeeded in our mission.
Bernard Sanders
The Public Record
Bernard Sanders is a prominent American politician and a member of the Democratic Party, known for his progressive policies and advocacy for social justice. He has served as a U.S. Senator from Vermont since 2007, having previously represented Vermont in the House of Representatives from 1991 to 2007. Sanders is recognized for his focus on issues such as income inequality, healthcare reform, and education, often emphasizing the need for systemic change to benefit working-class Americans.
I thank you Chairman Sanders, Ranking Member Dr. Cassidy, and Members of this Committee for advancing S. 1855--bipartisan legislation led by Senators Susan Collins and Jeanne Shaheen to renew the SDP and SDPI.
And if the system provides barriers, as Senator Sanders said, to drugs that could improve your care and your life and your health, then we haven't succeeded in our mission.
Today, we are going to be discussing one of the major health crises in America, and that is the diabetes epidemic.
We have got to make certain that the treatments available to people with diabetes are affordable for all Americans.
Now is the time for us to seriously combat the type 2 diabetes and obesity epidemics in America.
We need Congress to move swiftly to enact the SDP and SDPI funding, as contained in S. 1855.
I consider the high cost of prescription drugs to be one of the great crises facing our healthcare system.
If just 10 percent of people with obesity on Medicare took these drugs, it could cost Medicare up to $27 billion a year.
We need Congress to move swiftly and enact the STP and STPI funding contained in S. 1855.
We are going to have to take on 1,800 well-paid lobbyists from the pharmaceutical industry here and all of the campaign contributions that they make.
We need Congress to move swiftly and enact the STP and STPI funding contained in S. 1855.
The assurance of long-term funding is also important to attract new talent to this field and to maintain a pipeline of future generations of scientists to conduct T1D research.
I thank you Chairman Sanders, Ranking Member Dr. Cassidy, and Members of this Committee for advancing S. 1855--bipartisan legislation led by Senators Susan Collins and Jeanne Shaheen to renew the SDP and SDPI.
Now is the time for us to seriously combat the type 2 diabetes and obesity epidemics in America.
The assurance of long-term funding is also important to attract new talent to this field and to maintain a pipeline of future generations of scientists to conduct T1D research.
We have got to make certain that the treatments available to people with diabetes are affordable for all Americans.
If just 10 percent of people with obesity on Medicare took these drugs, it could cost Medicare up to $27 billion a year.
I consider the high cost of prescription drugs to be one of the great crises facing our healthcare system.
These two important drugs, up to 15 times more expensive in the United States than in other countries.
These two important drugs, up to 15 times more expensive in the United States than in other countries.
The idea that you are willing to go without paychecks to deal with--to walk on picket lines, to deal with all of the stuff out there in order to protect your patients is rather extraordinary.
In the United States of America, we spend almost twice as much per capita as any other major country.
What the nurses have told me, and I have had the opportunity on several occasions to sit down and talk with these nurses, is that what this strike has everything to do with is the safety of their patients.





